Related Experiment Videos
Genetically engineered vaccines: an overview
1Toxinology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702-5011, USA. dertzbau@detrick.army.mil
Plasmid
|March 26, 1998
Summary
Genetically engineered vaccines face manufacturing and immunogenicity challenges compared to conventional vaccines. Despite limitations, these advanced vaccines hold future promise for human and animal health.
Area of Science:
- Vaccinology
- Biotechnology
- Immunology
Background:
- The hepatitis B vaccine demonstrated early success for recombinant technology.
- No other recombinant engineered vaccine has been approved for human use.
- Economic factors make developing new recombinant vaccines to replace existing ones unlikely.
Purpose of the Study:
- To review current approaches and issues in the development of genetically engineered vaccines.
- To highlight the potential and limitations of recombinant subunit vaccines.
- To discuss the role of live attenuated vaccines in different global health contexts.
Main Methods:
- Review of existing literature on vaccine development.
- Analysis of manufacturing costs and regulatory hurdles for new vaccines.
- Comparison of immunogenicity and reactogenicity of recombinant versus conventional vaccines.
Main Results:
- Recombinant subunit vaccines are more costly and complex to manufacture.
- Higher purity standards for recombinant vaccines can lead to reduced immunogenicity.
- Live attenuated vaccines are less costly but carry higher risks in developed countries.
Conclusions:
- Recombinant subunit vaccines present challenges in cost, purity, and immunogenicity.
- Adjuvants and multi-antigenic designs can potentially overcome limitations of recombinant vaccines.
- Live attenuated vaccines remain important for specific global health needs, despite risks.